Tasigna
E584154
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Tasigna canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6311258 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tasigna Context triple: [Novartis, notableDrug, Tasigna]
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Toclafane
The Toclafane are a race of deadly, cybernetic spheres revealed to be the future remnants of humanity in the Doctor Who universe, serving as instruments of mass destruction under the Master.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Tasigna Target entity description: Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Toclafane
The Toclafane are a race of deadly, cybernetic spheres revealed to be the future remnants of humanity in the Doctor Who universe, serving as instruments of mass destruction under the Master.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
ⓘ
pharmaceutical drug ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| contraindicatedWith | strong CYP3A4 inhibitors ⓘ |
| developedBy | Novartis NERFINISHED ⓘ |
| dosageForm | capsule ⓘ |
| generation | second-generation BCR-ABL tyrosine kinase inhibitor ⓘ |
| hasActiveIngredient | nilotinib ⓘ |
| hasATCCode | L01EA03 ⓘ |
| hasBlackBoxWarning |
QT prolongation
ⓘ
sudden death risk ⓘ |
| hasBoxedWarningRegion | United States NERFINISHED ⓘ |
| hasChemicalClass | aminopyrimidine derivative ⓘ |
| hasGenericName | nilotinib ⓘ |
| hasPregnancyCategory | D (US, historical classification) ⓘ |
| hasTradeName | Tasigna NERFINISHED ⓘ |
| indicatedFor |
Ph+ CML in accelerated phase
ⓘ
Ph+ CML in chronic phase ⓘ Philadelphia chromosome–positive chronic myeloid leukemia ⓘ adult patients with Ph+ CML ⓘ pediatric patients with Ph+ CML ⓘ |
| isSecondGeneration | true ⓘ |
| mayCause |
QT interval prolongation
ⓘ
elevated lipase ⓘ elevated liver enzymes ⓘ headache ⓘ hyperglycemia ⓘ myelosuppression ⓘ nausea ⓘ pruritus ⓘ rash ⓘ |
| metabolizedBy | CYP3A4 NERFINISHED ⓘ |
| reduces | leukemic cell growth ⓘ |
| regulates | BCR-ABL–mediated cell proliferation ⓘ |
| requiresFastingAdministration | true ⓘ |
| requiresMonitoring |
complete blood counts
ⓘ
electrocardiogram ⓘ liver function tests ⓘ serum electrolytes ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
ABL1
NERFINISHED
ⓘ
BCR-ABL tyrosine kinase NERFINISHED ⓘ PDGFR NERFINISHED ⓘ c-KIT NERFINISHED ⓘ |
| usedFor |
treatment of imatinib-intolerant Ph+ CML
ⓘ
treatment of imatinib-resistant Ph+ CML ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Tasigna Description of subject: Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.